J B Hunt Transport Services Inc vs Merck & Co., Inc. — how do they compare? J B Hunt Transport Services Inc trades at $229 (market cap $21.45B), while Merck & Co., Inc. trades at $142.44 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 16.4× J B Hunt Transport Services Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and Merck & Co., Inc. for 98 Days on average.
| JBHT | MRK | |
|---|---|---|
Market Cap | $21.45B | $351.28B |
Volume | 1,028,680 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $298.41 | $156.43 |
52-Week Low | $137.09 | $82.49 |
Typical Hold Time | 45 Days | 98 Days |
Enterprise Value | $22.59B | $398.04B |
Dividend Yield | 0.79% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $222.64, down 1.46% on the day, amid a bearish technical signal and ongoing securities class action investigations. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected October 15, 2026. Fundamentals show a P/E of 31.67, net income margin of 5.31%, and strong cash flow from operations of $1.68 billion in 2025. Analyst consensus remains bullish with a $289.40 price target, though rising costs and legal scrutiny present headwinds.
The outlook is mixed; strong freight demand and earnings beats support upside potential, but near-term pressure from fuel costs and legal overhangs may limit gains. The stock offers value if operational efficiency improves, yet investors face risks from volatile diesel prices and potential litigation outcomes. The upcoming Q3 earnings will be critical for confirming the company's ability to navigate cost pressures.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →